- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06473662
Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects
June 19, 2024 updated by: Roger New
A Phase 2b, Open-label Randomized Comparative Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects Uncontrolled With Metformin Hydrochloride Treatment
The aim of the study was to compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label trial.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, NW1 0NH
- Diabetology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female aged 35 to 60 years (both inclusive)
- Type 2 diabetes mellitus diagnosed < 2 years prior to enrolment
- Glycated haemoglobin level ≥ 7% and ≤ 9.5%
- On stable oral monotherapy with metformin hydrochloride (1000 mg to 2500 mg/day) and regular diet and exercise regimen at least 12 weeks prior to enrolment
- Body mass index between 18 to 30 kg/m2
- Ability to perform capillary blood glucose measurements
- Willing to provide informed and written consent for the clinical trial
- Able to comply with all requirements of clinical trial protocol
Exclusion Criteria:
- Subject with history or evidence of hypersensitivity to insulin or metformin hydrochloride or its excipients
- Suffering from type 1 diabetes mellitus
- Received treatment with sulphonylureas or alpha-glucosidase inhibitors, Glucagonlike peptide-1 (GLP-1) receptor agonists or Sodium-glucose co-transporter 2 (SGLT2) inhibitors or meglitinides or pramlintide or thiazolidinediones within 3 months prior to enrolment
- Previously treated with insulin within 3 months prior to enrolment
- History of episodes of hypoglycaemia during 3 months prior to enrolment.
- Reduced awareness of hypoglycaemia or inability to identify and tackle hypoglycaemic episodes
- History of substantial weight loss defined as 5% decrease in body weight within the last 6 months
- Medical history of unstable angina within 1 year prior to enrolment
- History of tobacco or nicotine more than two packs/day within 3 months prior to enrolment
- Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within 1 year prior to enrolment) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking).
- History of gastrointestinal disorders which may potentially interfere with absorption of the investigational product
- Treatment with systemic corticosteroids or with inhalational corticosteroids (Beclomethasone or budesonide) within the 3 months prior to enrolment
- Likelihood of requiring treatment during the study period with prohibited medications mentioned (as defined in this clinical trial protocol)
- Female subject who is pregnant, lactating or planning pregnancy during the trial
- Female subject of childbearing age who is not willing to use adequate method of contraception during the study period
- Life expectancy of less than 6 months from screening
- Elective surgery or any other surgical procedure/s requiring general anaesthesia during the clinical trial
- Has participated in another research trial within 12 weeks prior to screening
History of diabetic ketoacidosis requiring hospitalization within 6 months prior to enrolment, case of proliferative retinopathy or advanced neuropathy
- Subject having any of the following laboratory results at screening
- Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
- Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) >3 times of upper limit normal
- Blood urea nitrogen (BUN) > 30 mg/dL
- Subject who has a positive serology for hepatitis B virus (HBV) or hepatitis C (HCV) or human immunodeficiency virus (HIV) infections at screening
- Subject who has undergone pancreatectomy or pancreas islet transplant or renal transplant
- Subject receiving or has received any immunomodulation medications within 1 year prior to enrolment
- Subject with history or evidence of diabetic complications (e.g. diabetic retinopathy, diabetic neuropathy, or diabetic nephropathy, etc.), cardiac disorders, or any other systemic complication due to diabetes, which in the opinion of the Investigator signifies subjects' ineligibility for the trial
- Has any concurrent disease or medical/surgical condition, which required treatment of more than 3 months and which in the opinion of the Investigator does not allow participation of the subject in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 75iu
Capsule containing 75iu recombinant human insulin administered two times per day
|
Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
|
Experimental: 150iu
Capsule containing 150iu recombinant human insulin administered two times per day
|
Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
|
Experimental: 300iu
Capsule containing 300iu recombinant human insulin administered two times per day
|
Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fall in HbA1c
Time Frame: 12 weeks
|
Fall in HbA1c
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Fasting Plasma Glucose
Time Frame: 12 weeks
|
Change in Fasting Plasma Glucose
|
12 weeks
|
Change in Post-Prandial Glucose
Time Frame: 12 weeks
|
Change in Post-Prandial Glucose
|
12 weeks
|
Changes in Lipids
Time Frame: 12 weeks
|
Change in plasma cholesterol and triglyceride
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 22, 2018
Primary Completion (Actual)
July 11, 2020
Study Completion (Actual)
July 11, 2020
Study Registration Dates
First Submitted
June 19, 2024
First Submitted That Met QC Criteria
June 19, 2024
First Posted (Actual)
June 25, 2024
Study Record Updates
Last Update Posted (Actual)
June 25, 2024
Last Update Submitted That Met QC Criteria
June 19, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Diabetology Ltd
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Treated With Insulin
-
Institute for Clinical and Experimental MedicineRecruitingType 2 Diabetes Treated With InsulinCzechia
-
Abbott Diabetes CareRecruitingType 2 Diabetes Treated With InsulinFinland
-
Steno Diabetes Center CopenhagenCompletedType 2 Diabetes Treated With InsulinDenmark
-
Hospital Universitario San IgnacioCompletedType 2 Diabetes Treated With InsulinColombia
-
DiabeloopAGIR à Dom; Icadom; CHU Grenoble AlpesCompletedType 2 Diabetes Treated With InsulinFrance
-
Klavs Würgler HansenSteno Diabetes Center Aarhus, DenmarkRecruitingType 2 Diabetes Treated With InsulinDenmark
-
Woodlands Health CampusTan Tock Seng HospitalRecruitingType 2 Diabetes Treated With InsulinSingapore
-
Boston Medical CenterNovo Nordisk A/SCompletedType 2 Diabetes Treated With InsulinUnited States
-
Centre hospitalier de l'Université de Montréal...CHU de Quebec-Universite Laval; Institut de Recherches Cliniques de MontrealWithdrawnType 2 Diabetes Treated With InsulinCanada
-
Abbott Diabetes CareNot yet recruitingType 2 Diabetes Treated With InsulinItaly
Clinical Trials on Oral insulin
-
University of Colorado, DenverJuvenile Diabetes Research Foundation; German Federal Ministry of Education... and other collaboratorsCompleted
-
Generex Biotechnology Corp.No longer availableType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus
-
Diasome PharmaceuticalsCompleted
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Japan
-
National Institute of Diabetes and Digestive and...National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedDiabetes Mellitus, Type 1United States, Canada
-
Generex Biotechnology Corp.Hoffmann-La Roche; Nextrials, Inc.; eResearch Technology, Inc.; OSMOS Clinical... and other collaboratorsUnknownDiabetes MellitusUnited States, Bulgaria, Canada, Ecuador, Poland, Puerto Rico, Romania, Russian Federation, Ukraine
-
Technical University of MunichUniversitaire Ziekenhuizen KU Leuven; Helmholtz Zentrum München; Medical University... and other collaboratorsActive, not recruitingDiabetes Mellitus, Type 1Belgium, Germany, Poland, Sweden, United Kingdom
-
National Institute of Diabetes and Digestive and...National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedDiabetes Mellitus, Type 1United States, Canada, Italy, Finland, Australia, United Kingdom
-
Technical University of MunichLudwig-Maximilians - University of Munich; Technische Universität Dresden; Helmholtz... and other collaboratorsCompleted
-
Oramed, Ltd.Hadassah Medical OrganizationCompletedType2 Diabetes Mellitus | Non-Alcoholic Steatohepatitis (NASH)Israel